GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Fosun Pharmaceutical (Group) Co Ltd (SHSE:600196) » Definitions » Piotroski F-Score

Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) Piotroski F-Score : 4 (As of May. 02, 2024)


View and export this data going back to 1998. Start your Free Trial

What is Shanghai Fosun Pharmaceutical (Group) Co Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Shanghai Fosun Pharmaceutical (Group) Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Shanghai Fosun Pharmaceutical (Group) Co's Piotroski F-Score or its related term are showing as below:

SHSE:600196' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 4   Max: 7
Current: 4

During the past 13 years, the highest Piotroski F-Score of Shanghai Fosun Pharmaceutical (Group) Co was 7. The lowest was 4. And the median was 4.


Shanghai Fosun Pharmaceutical (Group) Co Piotroski F-Score Historical Data

The historical data trend for Shanghai Fosun Pharmaceutical (Group) Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Fosun Pharmaceutical (Group) Co Piotroski F-Score Chart

Shanghai Fosun Pharmaceutical (Group) Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 4.00 7.00 5.00 4.00

Shanghai Fosun Pharmaceutical (Group) Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 5.00 4.00 4.00 -

Competitive Comparison of Shanghai Fosun Pharmaceutical (Group) Co's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fosun Pharmaceutical (Group) Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Fosun Pharmaceutical (Group) Co's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanghai Fosun Pharmaceutical (Group) Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Shanghai Fosun Pharmaceutical (Group) Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Net Income was 790.5 + 505.594 + 103.2 + 609.734 = ¥2,009 Mil.
Cash Flow from Operations was 936.764 + 651.632 + 952.577 + 917.312 = ¥3,458 Mil.
Revenue was 10524.472 + 9304.926 + 10699.421 + 10157.255 = ¥40,686 Mil.
Gross Profit was 5120.745 + 4223.926 + 4883.633 + 5079.549 = ¥19,308 Mil.
Average Total Assets from the begining of this year (Mar23)
to the end of this year (Mar24) was
(107379.375 + 112142.689 + 110767.244 + 113469.605 + 113745.789) / 5 = ¥111500.9404 Mil.
Total Assets at the begining of this year (Mar23) was ¥107,379 Mil.
Long-Term Debt & Capital Lease Obligation was ¥15,192 Mil.
Total Current Assets was ¥33,839 Mil.
Total Current Liabilities was ¥33,602 Mil.
Net Income was 1079.145 + 900.485 + 1294.605 + 986.972 = ¥4,261 Mil.

Revenue was 10962.742 + 10275.171 + 12328.777 + 10870.721 = ¥44,437 Mil.
Gross Profit was 5246.506 + 4940.827 + 6071.575 + 5575.927 = ¥21,835 Mil.
Average Total Assets from the begining of last year (Mar22)
to the end of last year (Mar23) was
(95774.597 + 98804.454 + 104329.254 + 107163.907 + 107379.375) / 5 = ¥102690.3174 Mil.
Total Assets at the begining of last year (Mar22) was ¥95,775 Mil.
Long-Term Debt & Capital Lease Obligation was ¥13,089 Mil.
Total Current Assets was ¥35,180 Mil.
Total Current Liabilities was ¥32,468 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Shanghai Fosun Pharmaceutical (Group) Co's current Net Income (TTM) was 2,009. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Shanghai Fosun Pharmaceutical (Group) Co's current Cash Flow from Operations (TTM) was 3,458. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar23)
=2009.028/107379.375
=0.01870963

ROA (Last Year)=Net Income/Total Assets (Mar22)
=4261.207/95774.597
=0.04449204

Shanghai Fosun Pharmaceutical (Group) Co's return on assets of this year was 0.01870963. Shanghai Fosun Pharmaceutical (Group) Co's return on assets of last year was 0.04449204. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Shanghai Fosun Pharmaceutical (Group) Co's current Net Income (TTM) was 2,009. Shanghai Fosun Pharmaceutical (Group) Co's current Cash Flow from Operations (TTM) was 3,458. ==> 3,458 > 2,009 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=15192.238/111500.9404
=0.13625211

Gearing (Last Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=13089.158/102690.3174
=0.12746244

Shanghai Fosun Pharmaceutical (Group) Co's gearing of this year was 0.13625211. Shanghai Fosun Pharmaceutical (Group) Co's gearing of last year was 0.12746244. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)=Total Current Assets/Total Current Liabilities
=33839.365/33602.092
=1.00706126

Current Ratio (Last Year: Mar23)=Total Current Assets/Total Current Liabilities
=35179.942/32468.08
=1.08352394

Shanghai Fosun Pharmaceutical (Group) Co's current ratio of this year was 1.00706126. Shanghai Fosun Pharmaceutical (Group) Co's current ratio of last year was 1.08352394. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Shanghai Fosun Pharmaceutical (Group) Co's number of shares in issue this year was 0. Shanghai Fosun Pharmaceutical (Group) Co's number of shares in issue last year was 2667.491. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=19307.853/40686.074
=0.4745568

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=21834.835/44437.411
=0.49136155

Shanghai Fosun Pharmaceutical (Group) Co's gross margin of this year was 0.4745568. Shanghai Fosun Pharmaceutical (Group) Co's gross margin of last year was 0.49136155. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar23)
=40686.074/107379.375
=0.37890027

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar22)
=44437.411/95774.597
=0.4639791

Shanghai Fosun Pharmaceutical (Group) Co's asset turnover of this year was 0.37890027. Shanghai Fosun Pharmaceutical (Group) Co's asset turnover of last year was 0.4639791. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+0+0+1+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Shanghai Fosun Pharmaceutical (Group) Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Shanghai Fosun Pharmaceutical (Group) Co  (SHSE:600196) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Shanghai Fosun Pharmaceutical (Group) Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Shanghai Fosun Pharmaceutical (Group) Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) Business Description

Traded in Other Exchanges
Address
No. 1289 Yishan Road, Building A, Fosun Technology Park, Shanghai, CHN, 200233
Shanghai Fosun Pharmaceutical (Group) Co Ltd is a specialty and generic drug manufacturing company. Shanghai Fosun maintains five business segments, including Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. Most of the company's revenue is generated by its Pharmaceutical manufacturing segment. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) Headlines

No Headlines